skip to Main Content

Tumor-Associated Immune Cells Hinder Frontline Chemotherapy Drug in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug’s action, research led by the University of Michigan Rogel Cancer Center found.

The chemotherapy drug gemcitabine is an anti-metabolite. It’s similar to normal metabolites taken up by the cell, but once inside it kills the cell by disrupting its functions — like a Trojan horse. Read more . . . 


Back To Top